安罗替尼治疗局部晚期或转移性甲状腺髓样癌
BACKGROUND: The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is poor, and there are few therapeutic options. Anlotinib has previously shown promising antitumor activity on MTC in preclinical models and a Phase I study.…
要点
- 安罗替尼在晚期或转移性MTC中显示出持久的抗肿瘤活性。
- 48周PFS率85.5%,56.9%患者获部分缓解,主要终点PFS未达到。
- 常见不良事件为手足综合征、高甘油三酯血症、胆固醇升高、乏力、蛋白尿。
核心结论
- 安罗替尼在局部晚期或转移性MTC中表现出持久的抗肿瘤活性,且不良事件谱可控。
研究设计与样本
- 给药方案为安罗替尼12 mg每日一次口服,用药两周停一周,直至疾病进展、死亡、不可接受毒性或撤回知情同意。
- 根据观察到的毒性调整剂量,主要终点为无进展生存期(PFS)。
主要发现
- 分析时主要终点PFS尚未达到。
- 研究者评估显示56.9%的患者出现部分缓解。
- 48周PFS率为85.5%。
- 最常见不良事件为手足综合征、高甘油三酯血症、胆固醇升高、乏力及蛋白尿。
临床怎么用
- 对于不可切除局部晚期或转移性MTC,安罗替尼12 mg每日一次口服、用药两周停一周方案可作为候选治疗选择。
- 治疗期间需监测手足综合征、血脂异常、乏力及蛋白尿等不良事件,并据毒性调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis of advanced or metastatic medullary thyroid carcinoma (MTC) is poor, and there are few therapeutic options. Anlotinib has previously shown promising antitumor activity on MTC in preclinical models and a Phase I study. This Phase II clinical trial was devised to confirm the antitumor activity of anlotinib in patients with advanced or metastatic MTC. METHODS: Patients with unresectable locally advanced or metastatic MTC received once daily oral anlotinib 12 mg, two weeks on/one week off, until disease progression, death, unacceptable toxicity, or withdrawal of consent for any reason. The dose was adjusted on the basis of observed toxicity. The primary endpoint was progression-free survival (PFS). RESULTS: Fifty-eight patients received anlotinib treatment. The primary endpoint PFS has not yet been reached at the time of analysis. On the basis of investigator assessments, 56.9% of patients experienced a partial response. PFS rate at 48 weeks was 85.5%. Forty-five patients had a ≥50% decrease in serum calcitonin concentration from baseline. The most common adverse events were hand-foot syndrome, hypertriglyceridemia, cholesterol elevation, fatigue, and proteinuria. CONCLUSIONS: Anlotinib demonstrated a durable antitumor activity with a manageable adverse event profile in locally advanced or metastatic MTC.
引用
- Sun Y, Du F, Gao M, et al. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer. Thyroid. 2018. PMID: 30142994. doi:10.1089/thy.2018.0022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。